Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Phase 2

Terminated

Conditions: Familial Partial Lipodystrophy
Metabolic Abnormalities

Interventions: Drug: REGN4461
Drug: Matching Placebo

First Posted Date: 2021-10-22

Last Posted Date: 2024-11-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT05088460

Locations: 🇺🇸
National Institute of Health, Bethesda, Maryland, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Excel Medical Clinical Trials - A Flourish Research Site, Boca Raton, Florida, United States

and more 5 locations

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

Phase 1

Terminated

Conditions: SARS-CoV-2

Interventions: Drug: imdevimab
Drug: REGN14256
Drug: Placebo
Drug: casirivimab + imdevimab

First Posted Date: 2021-10-18

Last Posted Date: 2024-04-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT05081388

Locations: 🇺🇸
PNS Clinical Research, LLC, Mission Viejo, California, United States
🇺🇸
PharmaTex Research, LLC, Amarillo, Texas, United States
🇺🇸
Ark Clinical Research, Long Beach, California, United States

and more 16 locations

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Phase 3

Terminated

Conditions: Immunocompromised

Interventions: Drug: casirivimab+imdevimab
Drug: Placebo

First Posted Date: 2021-10-12

Last Posted Date: 2023-07-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT05074433

Locations: 🇺🇸
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸
Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States
🇺🇸
Institute of Human Virology, Baltimore, Maryland, United States

and more 50 locations

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Pozelimab + Cemdisiran
Drug: Pozelimab
Drug: Cemdisiran
Other: Placebo

First Posted Date: 2021-10-07

Last Posted Date: 2025-04-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 335

Registration Number: NCT05070858

Locations: 🇺🇸
HonorHealth Neurology 2018, Scottsdale, Arizona, United States
🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States

and more 133 locations

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: casirivimab+imdevimab

First Posted Date: 2021-08-05

Last Posted Date: 2023-03-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT04992273

Locations: 🇺🇸
Advanced Research Center, Inc, Anaheim, California, United States
🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States

and more 4 locations

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced NSCLC

Interventions: Drug: REGN5093-M114
Drug: Cemiplimab

First Posted Date: 2021-07-29

Last Posted Date: 2025-02-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT04982224

Locations: 🇺🇸
Next Virginia, Fairfax, Virginia, United States
🇺🇸
University of California Irvine School of Medicine - Suite 400, Room 407, Orange, California, United States
🇺🇸
University of Colorado Hospital Anshutz Outpatient Pavillion, Denver, Colorado, United States

and more 8 locations

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Phase 3

Terminated

Conditions: Allergic Rhinitis Due to Cat Allergy

Interventions: Drug: REGN1908-1909
Drug: Matching Placebo

First Posted Date: 2021-07-29

Last Posted Date: 2024-06-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 446

Registration Number: NCT04981717

Locations: 🇺🇸
Integrated Research of Inland, Inc, Riverside, California, United States
🇺🇸
Allergy and Asthma Specialists PSC, Owensboro, Kentucky, United States
🇺🇸
Allergy Partners of Western North Carolina, Asheville, North Carolina, United States

and more 89 locations

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Active, not recruiting

Conditions: Chronic Rhinosinusitis With Nasal Polyposis

First Posted Date: 2021-07-13

Last Posted Date: 2024-05-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 717

Registration Number: NCT04959448

Locations: 🇺🇸
John Hopkins University School Of Medicine, Baltimore, Maryland, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM, Chicago, Illinois, United States

and more 78 locations

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pozelimab
Drug: Cemdisiran

First Posted Date: 2021-06-25

Last Posted Date: 2022-07-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT04940364

Locations: 🇬🇧
Regeneron Research Site, London, United Kingdom

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase 2

Terminated

Conditions: Merkel Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
Triple Negative Breast Cancer
Non-Small Cell Lung Cancer
Oropharynx Squamous Cell Carcinoma

Interventions: Drug: vidutolimod
Drug: cemiplimab

First Posted Date: 2021-06-07

Last Posted Date: 2024-11-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT04916002

Locations: 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 21 locations

Home Terms & Conditions Privacy Policy